106 related articles for article (PubMed ID: 30955853)
1. Patients' perspectives on the definition of cure in chronic myeloid leukemia.
Flynn KE; Mauro MJ; George G; Hinman A; Baim A; Kota V; Larson RA; Lipton JH; Thompson JE; Wadleigh M; Atallah E
Leuk Res; 2019 May; 80():40-42. PubMed ID: 30955853
[No Abstract] [Full Text] [Related]
2. Sustained molecular response in chronic myeloid leukemia deep responders treated with low dose tyrosine kinase inhibitors.
Cayssials E; Tartarin F; Guilhot J; Sorel N; Chomel JC; Leleu X; Guilhot F
Leuk Lymphoma; 2018 Mar; 59(3):766-769. PubMed ID: 28792265
[No Abstract] [Full Text] [Related]
3. Monitoring of leukemia stem cells in chronic myeloid leukemia patients.
Cui J; Zhu Z; Liu S; Li Q; Meng L; Cheng H; Zhong Z; Li W; You Y; Zhu X; Zou P
Leuk Lymphoma; 2018 Sep; 59(9):2264-2266. PubMed ID: 29334838
[No Abstract] [Full Text] [Related]
4. Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?
Qin YZ; Jiang Q; Jiang H; Li JL; Li LD; Zhu HH; Lai YY; Lu XJ; Liu YR; Jiang B; Huang XJ
Leuk Res; 2013 Sep; 37(9):1035-40. PubMed ID: 23810191
[TBL] [Abstract][Full Text] [Related]
5. Conditional relative survival among adult patients with chronic myeloid leukemia in the tyrosine kinase inhibitor era: a population-based study in the Netherlands.
Ector GICG; Visser O; Posthuma EFM; Westerweel PE; Janssen JJWM; Blijlevens NMA; Dinmohamed AG
Leukemia; 2021 Nov; 35(11):3291-3294. PubMed ID: 33603145
[No Abstract] [Full Text] [Related]
6. Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL Shows Deep Molecular Responses in Long-Term Post-Allogeneic Stem Cell Transplantation Chronic Myeloid Leukemia Patients.
Koren-Michowitz M; Shimoni A; Daraio F; Crasto F; Lorenzatti R; Volchek Y; Amariglio N; Gottardi E; Saglio G; Nagler A
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1852-5. PubMed ID: 26151304
[TBL] [Abstract][Full Text] [Related]
7. Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
Chen Z; Wang W; Cortes JE; Liu E; Miranda RN; Zhao C; Yuan J; Lu X; Yang W; Ameri MD; Kantarjian HM; Medeiros LJ; Hu S
Blood Cancer J; 2016 May; 6(5):e418. PubMed ID: 27152845
[No Abstract] [Full Text] [Related]
8. Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
Chen Z; Cortes JE; Jorgensen JL; Wang W; Yin CC; You MJ; Jabbour E; Kantarjian HM; Medeiros LJ; Hu S
Leukemia; 2016 Jul; 30(7):1606-9. PubMed ID: 26837843
[No Abstract] [Full Text] [Related]
9. Hepatitis B reactivation during treatment of tyrosine kinase inhibitors-Experience in 142 adult patients with chronic myeloid leukemia.
Wang YH; Liang JD; Sheng WH; Tien FM; Chen CY; Tien HF
Leuk Res; 2019 Jun; 81():95-97. PubMed ID: 31075669
[No Abstract] [Full Text] [Related]
10. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.
Rea D; Ame S; Berger M; Cayuela JM; Charbonnier A; Coiteux V; Cony-Makhoul P; Dubruille V; Dulucq S; Etienne G; Legros L; Nicolini F; Roche-Lestienne C; Escoffre-Barbe M; Gardembas M; Guerci-Bresler A; Johnson-Ansah H; Rigal-Huguet F; Rousselot P; Mahon FX;
Cancer; 2018 Jul; 124(14):2956-2963. PubMed ID: 29723417
[TBL] [Abstract][Full Text] [Related]
11. Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia.
Claudiani S; Apperley JF; Deplano S; Khorashad J; Foroni L; Palanicawandar R; Perry R; Milojkovic D
Am J Hematol; 2016 Nov; 91(11):E480-E481. PubMed ID: 27467708
[No Abstract] [Full Text] [Related]
12. Patient perceptions of treatment-free remission in chronic myeloid leukemia.
Villemagne Sanchez LA; O'Callaghan C; Gough K; Hall K; Kashima Y; Seymour JF; Schofield P; Ross DM
Leuk Lymphoma; 2018 Feb; 59(2):406-415. PubMed ID: 28617066
[TBL] [Abstract][Full Text] [Related]
13. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Jabbour E; Cortes J; Kantarjian H
Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
[TBL] [Abstract][Full Text] [Related]
14. Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia.
Racil Z; Klamova H; Voglova J; Faber E; Razga F; Zackova D; Buresova L; Cetkovsky P; Mayer J
Am J Hematol; 2010 May; 85(5):386-9. PubMed ID: 20425803
[No Abstract] [Full Text] [Related]
15. Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: does achievement of a stable major molecular response at any time point identify a privileged group of patients? A multicenter experience in Argentina and Uruguay.
Pavlovsky C; Giere I; Moiraghi B; Pavlovsky MA; Aranguren PN; García J; Fernandez I; Bengió R; Milone J; Labanca V; Uriarte R; Lombardi V; Reinoso FG; Magariños AE; Martinez L; Murro H; Lastiri F; Pavlovsky S
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):280-5. PubMed ID: 21658656
[TBL] [Abstract][Full Text] [Related]
16. Imatinib treatment of seropositive arthritis in a young woman with chronic myeloid leukemia.
Ames PR; Aye WW; Beatty C; O'Reilly D
J Rheumatol; 2008 Aug; 35(8):1682. PubMed ID: 18671330
[No Abstract] [Full Text] [Related]
17. BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival.
Pagnano KB; Bendit I; Boquimpani C; De Souza CA; Miranda EC; Zalcberg I; Larripa I; Nardinelli L; Silveira RA; Fogliatto L; Spector N; Funke V; Pasquini R; Hungria V; Chiattone CS; Clementino N; Conchon M; Moiraghi EB; Lopez JL; Pavlovsky C; Pavlovsky MA; Cervera EE; Meillon LA; Simões B; Hamerschlak N; Bozzano AH; Mayta E; Cortes J; Bengió RM;
Cancer Invest; 2015; 33(9):451-8. PubMed ID: 26288116
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias.
Ye YX; Zhou J; Zhou YH; Zhou Y; Song XB; Wang J; Lin L; Ying BW; Lu XJ
Asian Pac J Cancer Prev; 2014; 15(22):9961-6. PubMed ID: 25520136
[TBL] [Abstract][Full Text] [Related]
19. Genetic markers of stable molecular remission in chronic myeloid leukemia after targeted therapy discontinuation.
Smirnikhina SA; Chelysheva EY; Lavrov AV; Kochergin-Nikitsky KS; Mozgovoy IV; Adilgereeva EP; Shukhov OA; Petrova AN; Bykova AV; Abdullaev AO; Turkina AG; Kutsev SI
Leuk Lymphoma; 2018 Oct; 59(10):2512-2515. PubMed ID: 29424604
[No Abstract] [Full Text] [Related]
20. Longstanding remission of adult onset Still's disease under imatinib therapy in a patient with chronic myelogenous leukemia.
Nagasaki Y; Miyamoto T; Henzan H; Nagafuji K; Harada M; Akashi K
J Rheumatol; 2009 Jun; 36(6):1349-51. PubMed ID: 19509096
[No Abstract] [Full Text] [Related]
[Next] [New Search]
